The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.

OBJECTIVE We examined the expression status of p21^{Waf1/Cip1} and p57^{Kip2} in breast cancer as well as their relationship with clinicopathological factors. Moreover, the diagnostic value of gene promoter methylation of p21^Waf1/Cip1 and p57^Kip2 was assessed in breast cancer patients. METHODS This study involved 85 patients diagnosed with breast cancer and 36 patients with benign breast lesions. The expression of p21^{Waf1/Cip1} and p57^{Kip2} in cell lysates was analyzed by ELISA and Western blot, respectively. The gene promoter methylation of p21^Waf1/Cip1 and p57^Kip2 was examined in cell lysates by methylation specific PCR. RESULTS p21^{Waf1/Cip1} expression was higher while p57^{Kip2} level was lower in breast cancer patients compared to patients with benign breast lesions. The combined use of p21^{Waf1/Cip1} and p57^{Kip2} provided sensitivity and specificity of 82.35% and 86.11%, respectively. None of the malignant and benign breast tumors were found to be hypermethylated at p21^Waf1/Cip1 gene promoter. However, aberrant methylation of p57^Kip2 gene promoter was detected in 49 of 85 (57.65%) of breast cancer tumors. High p21^{Waf1/Cip1} level was associated with high grade, late stages and lymph node involvement, whereas low p57^{Kip2} level was correlated with high grade and HER2 overexpressing breast cancer. Moreover, hypermethylated p57^Kip2 gene promoter was associated with high grade. CONCLUSION Our findings show that the overexpression of p21^{Waf1/Cip1}, down-expression of p57^{Kip2} and gene promoter methylation of p57^Kip2 could be considered as promising diagnostic markers for breast cancer.

[1]  Chang-Yuan Wei,et al.  Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance. , 2015, International journal of clinical and experimental pathology.

[2]  K. Nan,et al.  High Skp2/Low p57Kip2 Expression is Associated with Poor Prognosis in Human Breast Carcinoma , 2015, Breast cancer : basic and clinical research.

[3]  P. Kaldis,et al.  Cdks, cyclins and CKIs: roles beyond cell cycle regulation , 2013, Development.

[4]  R. Zhao,et al.  CDK inhibitor p57Kip2 is downregulated by Akt during HER2-mediated tumorigenicity , 2013, Cell cycle.

[5]  M. El-Shinawi,et al.  Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer , 2011, Medical oncology.

[6]  S. Perrotta,et al.  p57Kip2 and Cancer: Time for a Critical Appraisal , 2011, Molecular Cancer Research.

[7]  G. Mills,et al.  Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. , 2010, Biochemical and biophysical research communications.

[8]  T. Hunter,et al.  Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors , 2010, Cell cycle.

[9]  P. S. Larson,et al.  CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer , 2008, BMC Cancer.

[10]  R. Liang,et al.  Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma , 2005, Leukemia.

[11]  G. Blandino,et al.  A Role of p73 in Mitotic Exit* , 2005, Journal of Biological Chemistry.

[12]  S. Toyooka,et al.  Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. , 2004, Oncology reports.

[13]  Yong Liao,et al.  Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients , 2004, Clinical Cancer Research.

[14]  P. Lønning,et al.  Genetic and Epigenetic Changes in p21 and p21B Do Not Correlate with Resistance to Doxorubicin or Mitomycin and 5-Fluorouracil in Locally Advanced Breast Cancer , 2004, Clinical Cancer Research.

[15]  A. Harris,et al.  Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis , 2003, Breast Cancer Research.

[16]  A. Borowsky,et al.  An Antisense Oligodeoxynucleotide to p21Waf1/Cip1 Causes Apoptosis in Human Breast Cancer Cells1 , 2003 .

[17]  V. Kosma,et al.  p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis , 2003, Journal of clinical pathology.

[18]  R. Weiss,et al.  Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1). , 2003, Cancer letters.

[19]  Ying Li,et al.  AKT/PKB Phosphorylation of p21Cip/WAF1 Enhances Protein Stability of p21Cip/WAF1 and Promotes Cell Survival* , 2002, The Journal of Biological Chemistry.

[20]  A. Harris,et al.  Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis. , 2001, European journal of cancer.

[21]  Stefanie Dimmeler,et al.  Akt-Dependent Phosphorylation of p21Cip1 Regulates PCNA Binding and Proliferation of Endothelial Cells , 2001, Molecular and Cellular Biology.

[22]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[23]  K. Miyazono,et al.  Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation , 1999, The EMBO journal.

[24]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[25]  R. DePinho,et al.  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Z. Shao,et al.  p21/waf1/cip1 and mdm‐2 expression in breast carcinoma patients as related to prognosis , 1997, International journal of cancer.

[27]  X. -. Li,et al.  Posttranscriptional regulation of p21WAF1/CIP1 expression in human breast carcinoma cells. , 1996, Cancer research.

[28]  A. Harris,et al.  Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  A. Harris,et al.  p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. , 1996, British Journal of Cancer.

[30]  G. Hannon,et al.  Functional Analysis of a p21WAF1,CIP1,SDI1 Mutant (Arg94 → Trp) Identified in a Human Breast Carcinoma , 1996, The Journal of Biological Chemistry.

[31]  Xiao-Fan Wang,et al.  Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Hannon,et al.  Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair , 1994, Nature.

[33]  D. Givol,et al.  Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.

[34]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[35]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[36]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[37]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[39]  A. Hergovich,et al.  Cell-Cycle Control and DNA-Damage Signaling in Mammals , 2016 .

[40]  F. Jin,et al.  Clinical implications of p57 KIP2 expression in breast cancer. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[41]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[42]  K. Tory,et al.  Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. , 2000, Pathology, research and practice.